Dali Pharmaceuticalco.,Ltd reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 59.19 million compared to CNY 69.67 million a year ago. Revenue was CNY 59.57 million compared to CNY 69.68 million a year ago.

Net loss was CNY 10.78 million compared to CNY 8.49 million a year ago. Basic loss per share from continuing operations was CNY 0.0491 compared to CNY 0.0386 a year ago. Diluted loss per share from continuing operations was CNY 0.0491 compared to CNY 0.0386 a year ago.